anmelden
OMX Copenhagen 20
1.614,22
PKT
-3,08
PKT
-0,19
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen 20-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 26.11.21 | Novo Nordisk Outperform | Bernstein Research | |
| 22.11.21 | Novo Nordisk Overweight | Barclays Capital | |
| 19.11.21 | Novo Nordisk Neutral | UBS AG | |
| 18.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 15.11.21 | A.P. Moeller - Maersk A-S (B) Neutral | JP Morgan Chase & Co. | |
| 11.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.11.21 | Novo Nordisk Neutral | Credit Suisse Group | |
| 04.11.21 | Novo Nordisk Overweight | Barclays Capital | |
| 04.11.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.11.21 | Novo Nordisk Outperform | Bernstein Research | |
| 03.11.21 | Novo Nordisk Neutral | UBS AG | |
| 03.11.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 01.11.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 29.10.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 29.10.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 27.10.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 25.10.21 | A.P. Moeller - Maersk A-S (B) Buy | UBS AG | |
| 18.10.21 | Novo Nordisk Overweight | Barclays Capital | |
| 14.10.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 28.09.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 14.09.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 02.09.21 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 01.09.21 | Novo Nordisk Buy | Deutsche Bank AG | |
| 26.08.21 | Novo Nordisk Neutral | UBS AG | |
| 23.08.21 | Novo Nordisk Neutral | Credit Suisse Group | |
| 20.08.21 | Novo Nordisk Outperform | Bernstein Research | |
| 17.08.21 | Novo Nordisk Neutral | UBS AG | |
| 17.08.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 16.08.21 | A.P. Moeller - Maersk A-S (B) Neutral | JP Morgan Chase & Co. | |
| 06.08.21 | Novo Nordisk Buy | Deutsche Bank AG | |
| 06.08.21 | Novo Nordisk Outperform | Bernstein Research | |
| 06.08.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 05.08.21 | Novo Nordisk Overweight | Barclays Capital | |
| 05.08.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 04.08.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.08.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 04.08.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 30.07.21 | A.P. Moeller - Maersk A-S (B) Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 29.07.21 | Novo Nordisk Overweight | JP Morgan Chase & Co. |
